Literature DB >> 16849478

Local intrahepatic CD8+ T cell activation by a non-self-antigen results in full functional differentiation.

Sherry A Wuensch1, Robert H Pierce, I Nicholas Crispe.   

Abstract

The response of T cells to liver Ags sometimes results in immune tolerance. This has been proposed to result from local, intrahepatic priming, while the expression of the same Ag in liver-draining lymph nodes is believed to result in effective immunity. We tested this model, using an exogenous model Ag expressed only in hepatocytes, due to infection with an adeno-associated virus vector. T cell activation was exclusively intrahepatic, yet in contrast to the predictions of the current model, this resulted in clonal expansion, IFN-gamma synthesis, and cytotoxic effector function. Local activation of naive CD8(+) T cells can therefore cause full CD8(+) T cell activation, and hepatocellular presentation cannot be used to explain the failure of CTL effector function against some liver pathogens such as hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849478     DOI: 10.4049/jimmunol.177.3.1689

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Role of interleukin-21 in HBV infection: friend or foe?

Authors:  Yongyin Li; Libo Tang; Jinlin Hou
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

3.  TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

Authors:  Marcin Cebula; Mathias Riehn; Upneet Hillebrand; Ramona F Kratzer; Florian Kreppel; Georgia Koutsoumpli; Toos Daemen; Hansjörg Hauser; Dagmar Wirth
Journal:  Mol Ther       Date:  2017-07-14       Impact factor: 11.454

4.  Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses.

Authors:  Fang Wu; Sherry A Wuensch; Mitra Azadniv; Mohammad R Ebrahimkhani; I Nicholas Crispe
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

5.  In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.

Authors:  Andrea Annoni; Brian D Brown; Alessio Cantore; Lucia Sergi Sergi; Luigi Naldini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

6.  Intrahepatic lymphocyte expression of dipeptidyl peptidase I-processed granzyme B and perforin induces hepatocyte expression of serine proteinase inhibitor 6 (Serpinb9/SPI-6).

Authors:  Heather W Stout-Delgado; Yonas Getachew; Bonnie C Miller; Dwain L Thiele
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

7.  Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice.

Authors:  Matthew Giannandrea; Robert H Pierce; Ian Nicholas Crispe
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 8.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

9.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

10.  Liver is able to activate naïve CD8+ T cells with dysfunctional anti-viral activity in the murine system.

Authors:  John R Lukens; Joseph S Dolina; Taeg S Kim; Robert S Tacke; Young S Hahn
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.